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``Improvements that make vaccine delivery easier
and safer, decrease dependency on the cold chain
or reduce number of immunization interventions
needed, could have a significant impact…``
Friede & Aguado, ADDR 57 (2005) 325-331
Initiative for Vaccine Research , WHO
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‘Ideal’ vaccine: the SAFE concept
Stable under high temperature and freezing conditions
Affordable, allowing large scale vaccination campaigns in
developing countries
Fast: single-shot (pulsatile release?) increasing compliance,
coverage of certain age groups (i.e. adolescents)
Easy application (nasal, topical, oral, pulmonary), avoiding
parenteral administration and risk of infection
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Disease burden in developing countries 
caused by unsafe injections
Number Percentage
Hep B  21.7 M 33%
Hep C 2 M 42%




HIV infection changing paradigm: a ‘tale of two infections’
Picker & Watkins, Nat Immunol 6 (2005) 430 
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Mucosal surfaces are the port-of-entry for infectious diseases
Role of Mucosal T-cells in HIV:
HIV/SIV infect  mucosal CD4+CCR5+ T-cells
rapid depletion by lytic viral replication
viral reservoirs in resting memory T-cells
functional and structural degradation of mucosal tissue
increased antigen exposure leads to opportunistic infections (OIs)
OIs trigger activation of CD4+CCR5+ T-cells 
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Picker & Watkins, Nat Immunol 6 (2005) 430
Haase Nat Rev Immunol 5 (2005) 783  




‘’There has been minimal global effort for
clinical trial assessment of vaccine
approaches that have the potential to protect
at mucosal surfaces during early events…’’
‘’…strategies are needed that could elicit
mucosal immune responses in addition to
systemic immune responses…’’






Bronchial Associated Lymphoid Tissue (BALT):
• BALT is not a constitutive structure of the healthy adult lung.
• Induced by high antigen load, infection, inflammation.
• Sampling from lumen by epithelial cells, not through lymph
system.
• Formed independently of lymphotoxin α (Ltα), inducer of 2°
lymphoid organs in embryogenesis and modulator of immune
response.
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Moyron-Quiroz, Nat Med 10 (2004) 927
Respiratory immunity in the absence of lymphoid
structures: iBALT
• Lymphotoxin (LT) α−/− lack lymph nodes and PP, show disrupted spleen and NALT
• LTα KO mice form lymphoid structures de novo in the lung on influenza challenge
• Formation suggested to be mediated by epithelial cells, affecting Mø, DC, T-cells, etc.
• ‘’iBALT’’ structures are capable of staging adaptive immune response on 2° infection
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1° infection 2° infection
DC migration &
presentation
Teff: effector cells Tem: effector memory cells  Tcm: central memory cells
Effector Lymphoid Tissue (ELT)




• Defines and includes pool of Tem/Teff cells outside 2° lymphoid
tissue.
• Formation is the result of stable retention of T-cells post AG
stimulation.
• Teff and Tem cells stably localized at port-of-pathogen-entry for
fast reaction to 2° infection.
• Not limited to mucosal tissues, includes all organs exposed to
pathogens.




• Which cells, mediators, receptors play important role
in ELT formation?
• How is selective recruitment, retention, long-term
survival and replenishment of Tem/Teff cells regulated?
• Orchestration of immune response between ELT and
2° lymphoid tissue on 2° infection?








Immunity at primary infection site
Mucosal and systemic immunity
Reduced need for medical staff
Non-invasive




• 2.2 million deaths per year
• 2 billion infected
• 8 million new cases per year
• 10-15 individuals annually infected by single untreated patient
• BCG is not a satisfactory vaccine
• No vaccine available for HIV patients more exposed to active TB
• Drug regimens are complicated, poor compliance, development of
resistant strains
• MDR-TB rising, therapy is expensive
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Example: the M. tuberculosis genome
• 4.411 Mbp, 90.8% protein coding genes
• Genes with attributed functions: 2,441, unknown: 606
• Specific open reading frames (ORF) absent from M.
bovis: 129.
• Absent ORF represent information for potential anti-




DNA Vaccines for Tuberculosis
• Ag85 complex (Ag85A, B and C) induces humoral and cell-mediated
immunity, protects against M. tuberculosis challenge (Ag85A most efficient),
encodes fibronectin binding protein. Huygen et al., Nature Med. 2, 893-898,
1996.
• hsp65 induces specific cellular and humoral responses, protects against M.
tuberculosis challenge, encodes a 65 kDa heat shock protein (hsp). Tascon
et al., Nature Med. 2, 888-892, 1996.
• ESAT-6 induces T cell response and IFN-γ secretion. Olsen et al., Infect.
Immun. 69, 2773-2778, 2001.
• Other plasmids encoding proteins related to different stages of M.
tuberculosis development.
GPEN 2006
Optimisation of DNA vaccines - increasing cellular/humoral
responses by:
• immunostimulatory sequences neighbouring CpG motifs:
pupuCGpypy (pu: A,G; py: T, C)
• integration of genetic information for cytokines:
-> Th1 cytokines (IL-12, IFN-γ) to stimulate cytotoxic
T-cell (CTL) response




DNA vaccines: formulation parameters
• DNA vaccine parameters: 
polyepitope, size, enzyme stability
•  Nature pathogen/disease: 
viral/bacterial, route of entry, progression of disease
•  Desired immune response:
Humoral, CTL, Th1/Th2
•  Delivery system:
Administration route, targeting, delivery device
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DNA vaccines: administration routes alternative to injection
1) mucosal: oral, nasal, vaginal, rectal, pulmonary
• interaction with local immunoactive tissues, e.g. Peyer’s
patches
• induction of both, local and systemic immune response (i.e.,
IgA and IgG)
• cross-talk between mucosal tissues (Mucosal Associated
Lymphoid Tissues, MALT)
• strong involvement of dendritic cells (DC), especially in the
lung
2) Gene gun
• intradermal injection of DNA vaccine coated gold particles




• DNA coated particles are
injected into the cells:
improvement of uptake by
Langerhans’ cells
• less priming by CpG motifs
through TlR interaction
• lower expression of CD, MHC
• resulting in Th2 bias
Aims:
1. In vitro testing Calu-3, DC
2. Evaluate T-cell response
3. Compare i.m. to pulmonary
application















Polymer-based DNA vaccine delivery systems
• condensation of DNA by electrostatic interactions
• reduction in size, zetapotential





• Chitosan n.p. were proven to be efficient carriers for oral delivery
of DNA vaccine against peanut allergy (Leong et al.)
• Chitosan-DNA complexes (nano-size) showed good pulmonary
transfection in-vivo (Köping-Höggård et al.)
• Chitosan-DNA complexes (nano-size) were shown to be safe and












Characterization of size, zetapotential, DNase protection,
DNA loading and release














Loading Efficiency (LE) =(total DNA - free DNA)     total DNA x 100 %
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• Size of chitoplexes: 200 - 400 nm
• Charge at pH 5.5: 20 - 27 mV
– strongly dependent on pH
– positive charge good for cell attachment and
uptake
• Loading Efficiency: > 95%
– efficient procedure; no material loss
→ Size, zetapotential and LE independent of (N/P) ratio
→ Strong charge interactions
Characteristics of chitoplexes
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Is DNA in chitoplexes protected against
nucleic acid degradation by chitosan?
   → Incubation with DNase I
When the chitosan in chitoplexes is
degraded by enzymes, is the DNA released
in intact form?













Analysis by agarose gel
electrophoresis
Incubation with DNase I (1)
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Naked DNA Ratio (N/P) 2:1 Ratio (N/P) 3:1







Incubation with DNase I (2)
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Incubation with DNase I (3)
Naked DNA (N/P) 2:1 (N/P) 3:1 (N/P) 4:1 (N/P) 5:1 (N/P) 6:1







• Compared with naked DNA, the DNA in chitoplexes
is protected against nucleic acid degradation by
chitosan
• The more chitosan, the more protection?
– Ratio (N/P) 2:1 is less protected
– no significant differences at ratios between  (N/P)
3:1 and 6:1














degradation products: oligochitosan 2 - 6
• Chitosanase present in micro-organisms and plants
• used chitosanase: from Streptomyces griseus
Stop solution: 1M KOH
In humans: degradation by lysozyme













DNA in aqueous phase
-
+
55 min, 100 V
Analysis by agarose gel
electrophoresis
Incubation with chitosanase (2)
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Chitoplexes are partly degraded by chitosanase.
After enzymatic degradation of chitoplexes, DNA
is intactly released.
Only free DNA, no chitoplexes, are extracted.
After extraction some free DNA stays at loading position. 
Free DNA is released and partially fragmented.




Immunogenicity induces humoral and cellular immune responses
low effective dosage in animal models
Safety unable to revert into virulence,
no toxic treatment needed as in live vaccines
Engineering vectors easy to manipulate, fast testing
combinatorial approaches easily adapted
Manufacture low costs, reproducible large-scale production
Stability temperature-stable than conventional vaccines
long shelf-life




• adequate animal models
• extention of plasmid survival: better immune response?
• will prolongation of antigen synthesis elicit autoimmune
responses?
• interindividual differences in immune responses?
• dendritic cell targeting
• selection of antigens -> genomics approach (inverse vaccinology)








































RTC: rabbit tracheal epithelial cells, Calu-3: human submucosal gland cell line,
16HBE14o-: human bronchial cell line, Papp: apparent permeability (10-7cm s-1), CFTR:
Cystic Fibrosis Transmembrane Regulator protein, P-gp: P-glycoprotein
# = own data, all other data taken from current literature.
Comparison of cell culture models of the airway epithelium
           in vivo     PTC#    RTC    Calu-3      16HBE14o-
Tight junctions   +     +       +        +   +
Papp mannitol 5-10      1.5-3.5 1.2-2.8    0.5-1.0#  3.1
Cilia   +     +       +        +     +
Mucus   +     +       +        +      -
CFTR expression   +             ?             ?        +   +
P-gp expression   +     +       ?        +#   ?  
Cell yield/trachea           -           6x107   2.5x107            -   -
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Calu-3 cells, grown at air interface, 100X
Calu-3 cells: mucus staining Periodic Schiff’s, Alcian Blue
• Calu-3 express human MUC1,
MUC4, MUC5 and MUC5B genes
• Calu-3 secrete proteoglycans and
  sulfated mucins
• Calu-3 apical surface fluid exerts
  anti-bacterial activity
• Calu-3 are used for investigation of
mucus as a barrier to gene delivery
Meaney et al., Cell culture models of biological barriers, Harwood 2002
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Uptake by human bronchial epithelial cells 
(Calu-3) in vitro
Bivas-Benita et al., Eur. J. Pharm. Biopharm. 58 (2004) 1-6


































































































































Bivas-Benita et al., submitted
Maturation of DCs in culture
Induced in-vivo T cell responses
toward M. tuberculosis sonicate.
Chitosan n.p. enhanced IFN-g production
in comparison to the DNA solution
The pulmonary (e.t.) immunization had a







Mucosal surfaces of the lung are suitable for eliciting local and
systemic immune response.
Optimization of both vaccines and carrier systems for mucosal
application, especially if applied pulmonary, is necessary.
DNA-vaccine offer advantages over subunit vaccines
(combination of antigenic structures and adjuvants, stability).
Problems of parenterally applied vaccines are avoided
(patient compliance, risk of infection, infrastructure).
